Topical Diacerein Decreases Skin and Splenic CD11c
        + Dendritic Cells in Psoriasis.

Susanne Brunner; Andrea Ramspacher; Caroline Rieser; Julia Leitner; Hannah Heil; Michael Ablinger; Julia Tevini; Monika Wimmer; Andreas Koller; Josefina Piñón Hofbauer; Thomas Felder; Johann Bauer; Barbara Kofler; Roland Lang; Verena Wally

doi:10.3390/ijms24054324

Topical Diacerein Decreases Skin and Splenic CD11c + Dendritic Cells in Psoriasis.

Susanne Brunner^* (First author), Andrea Ramspacher (Co-author), Caroline Rieser, Julia Leitner, Hannah Heil, Michael Ablinger (Co-author), Julia Tevini (Co-author), Monika Wimmer (Co-author), Andreas Koller (Co-author), Josefina Piñón Hofbauer (Co-author), Thomas Felder (Co-author), Johann Bauer (Co-author), Barbara Kofler (Co-author), Roland Lang (Last author), Verena Wally (Last author)

^*Corresponding author for this work

Research output: Contribution to journal › Original Article (Journal) › peer-review

1 Citation (Web of Science)

Abstract

Psoriasis is an inflammatory skin disease characterized by increased neo-vascularization, keratinocyte hyperproliferation, a pro-inflammatory cytokine milieu and immune cell infiltration. Diacerein is an anti-inflammatory drug, modulating immune cell functions, including expression and production of cytokines, in different inflammatory conditions. Therefore, we hypothesized that topical diacerein has beneficial effects on the course of psoriasis. The current study aimed to evaluate the effect of topical diacerein on imiquimod (IMQ)-induced psoriasis in C57BL/6 mice. Topical diacerein was observed to be safe without any adverse side effects in healthy or psoriatic animals. Our results demonstrated that diacerein significantly alleviated the psoriasiform-like skin inflammation over a 7-day period. Furthermore, diacerein significantly diminished the psoriasis-associated splenomegaly, indicating a systemic effect of the drug. Remarkably, we observed significantly reduced infiltration of CD11c⁺ dendritic cells (DCs) into the skin and spleen of psoriatic mice with diacerein treatment. As CD11c⁺ DCs play a pivotal role in psoriasis pathology, we consider diacerein to be a promising novel therapeutic candidate for psoriasis.

Original language	English
Journal	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume	24
Issue number	5
DOIs	https://doi.org/10.3390/ijms24054324
Publication status	Published - 21 Feb 2023

Keywords

MOLECULAR-MECHANISMS
INFLAMMATION
MANAGEMENT
DISEASE
RHEIN
NEUTROPHILS
DELIVERY
MICE

Access to Document

10.3390/ijms24054324

Treatment of psoriasiform-like skin inflammation with diacerein
Wally, V. (PI), Kofler, B. (CoPI) & Lang, R. (CoPI)
1/06/18 → 1/06/20
Project: Research

Cite this

Brunner, S., Ramspacher, A., Rieser, C., Leitner, J., Heil, H., Ablinger, M., Tevini, J., Wimmer, M., Koller, A., Piñón Hofbauer, J., Felder, T., Bauer, J., Kofler, B., Lang, R., & Wally, V. (2023). Topical Diacerein Decreases Skin and Splenic CD11c + Dendritic Cells in Psoriasis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(5). https://doi.org/10.3390/ijms24054324

@article{70934d80bd7e461b951964fffa40efb9,

title = "Topical Diacerein Decreases Skin and Splenic CD11c + Dendritic Cells in Psoriasis.",

abstract = "Psoriasis is an inflammatory skin disease characterized by increased neo-vascularization, keratinocyte hyperproliferation, a pro-inflammatory cytokine milieu and immune cell infiltration. Diacerein is an anti-inflammatory drug, modulating immune cell functions, including expression and production of cytokines, in different inflammatory conditions. Therefore, we hypothesized that topical diacerein has beneficial effects on the course of psoriasis. The current study aimed to evaluate the effect of topical diacerein on imiquimod (IMQ)-induced psoriasis in C57BL/6 mice. Topical diacerein was observed to be safe without any adverse side effects in healthy or psoriatic animals. Our results demonstrated that diacerein significantly alleviated the psoriasiform-like skin inflammation over a 7-day period. Furthermore, diacerein significantly diminished the psoriasis-associated splenomegaly, indicating a systemic effect of the drug. Remarkably, we observed significantly reduced infiltration of CD11c+ dendritic cells (DCs) into the skin and spleen of psoriatic mice with diacerein treatment. As CD11c+ DCs play a pivotal role in psoriasis pathology, we consider diacerein to be a promising novel therapeutic candidate for psoriasis.",

keywords = "MOLECULAR-MECHANISMS, INFLAMMATION, MANAGEMENT, DISEASE, RHEIN, NEUTROPHILS, DELIVERY, MICE",

author = "Susanne Brunner and Andrea Ramspacher and Caroline Rieser and Julia Leitner and Hannah Heil and Michael Ablinger and Julia Tevini and Monika Wimmer and Andreas Koller and {Pi{\~n}{\'o}n Hofbauer}, Josefina and Thomas Felder and Johann Bauer and Barbara Kofler and Roland Lang and Verena Wally",

note = "Brunner, Ramspacher, Rieser, Leitner, Heil, Kofler: Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; Ablinger, Wimmer, Hofbauer, Wally: EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; Tevini, Felder: Department of Laboratory Medicine, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; Koller: Research Program for Experimental Dermatology and Glaucoma Research, Department of Ophthalmology and Optometry, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; Bauer, Lang: Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria",

year = "2023",

month = feb,

day = "21",

doi = "10.3390/ijms24054324",

language = "English",

volume = "24",

journal = "INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES",

issn = "1422-0067",

publisher = "MDPI",

number = "5",

}

Brunner, S, Ramspacher, A, Rieser, C, Leitner, J, Heil, H, Ablinger, M , Tevini, J , Wimmer, M , Koller, A , Piñón Hofbauer, J , Felder, T , Bauer, J , Kofler, B , Lang, R & Wally, V 2023, 'Topical Diacerein Decreases Skin and Splenic CD11c + Dendritic Cells in Psoriasis.', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 24, no. 5. https://doi.org/10.3390/ijms24054324

TY - JOUR

T1 - Topical Diacerein Decreases Skin and Splenic CD11c + Dendritic Cells in Psoriasis.

AU - Brunner, Susanne

AU - Ramspacher, Andrea

AU - Rieser, Caroline

AU - Leitner, Julia

AU - Heil, Hannah

AU - Ablinger, Michael

AU - Tevini, Julia

AU - Wimmer, Monika

AU - Koller, Andreas

AU - Piñón Hofbauer, Josefina

AU - Felder, Thomas

AU - Bauer, Johann

AU - Kofler, Barbara

AU - Lang, Roland

AU - Wally, Verena

N1 - Brunner, Ramspacher, Rieser, Leitner, Heil, Kofler: Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; Ablinger, Wimmer, Hofbauer, Wally: EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; Tevini, Felder: Department of Laboratory Medicine, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; Koller: Research Program for Experimental Dermatology and Glaucoma Research, Department of Ophthalmology and Optometry, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria; Bauer, Lang: Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria

PY - 2023/2/21

Y1 - 2023/2/21

N2 - Psoriasis is an inflammatory skin disease characterized by increased neo-vascularization, keratinocyte hyperproliferation, a pro-inflammatory cytokine milieu and immune cell infiltration. Diacerein is an anti-inflammatory drug, modulating immune cell functions, including expression and production of cytokines, in different inflammatory conditions. Therefore, we hypothesized that topical diacerein has beneficial effects on the course of psoriasis. The current study aimed to evaluate the effect of topical diacerein on imiquimod (IMQ)-induced psoriasis in C57BL/6 mice. Topical diacerein was observed to be safe without any adverse side effects in healthy or psoriatic animals. Our results demonstrated that diacerein significantly alleviated the psoriasiform-like skin inflammation over a 7-day period. Furthermore, diacerein significantly diminished the psoriasis-associated splenomegaly, indicating a systemic effect of the drug. Remarkably, we observed significantly reduced infiltration of CD11c+ dendritic cells (DCs) into the skin and spleen of psoriatic mice with diacerein treatment. As CD11c+ DCs play a pivotal role in psoriasis pathology, we consider diacerein to be a promising novel therapeutic candidate for psoriasis.

AB - Psoriasis is an inflammatory skin disease characterized by increased neo-vascularization, keratinocyte hyperproliferation, a pro-inflammatory cytokine milieu and immune cell infiltration. Diacerein is an anti-inflammatory drug, modulating immune cell functions, including expression and production of cytokines, in different inflammatory conditions. Therefore, we hypothesized that topical diacerein has beneficial effects on the course of psoriasis. The current study aimed to evaluate the effect of topical diacerein on imiquimod (IMQ)-induced psoriasis in C57BL/6 mice. Topical diacerein was observed to be safe without any adverse side effects in healthy or psoriatic animals. Our results demonstrated that diacerein significantly alleviated the psoriasiform-like skin inflammation over a 7-day period. Furthermore, diacerein significantly diminished the psoriasis-associated splenomegaly, indicating a systemic effect of the drug. Remarkably, we observed significantly reduced infiltration of CD11c+ dendritic cells (DCs) into the skin and spleen of psoriatic mice with diacerein treatment. As CD11c+ DCs play a pivotal role in psoriasis pathology, we consider diacerein to be a promising novel therapeutic candidate for psoriasis.

KW - MOLECULAR-MECHANISMS

KW - INFLAMMATION

KW - MANAGEMENT

KW - DISEASE

KW - RHEIN

KW - NEUTROPHILS

KW - DELIVERY

KW - MICE

U2 - 10.3390/ijms24054324

DO - 10.3390/ijms24054324

M3 - Original Article (Journal)

C2 - 36901755

SN - 1422-0067

VL - 24

JO - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

IS - 5

ER -

Topical Diacerein Decreases Skin and Splenic CD11c + Dendritic Cells in Psoriasis.

Abstract

Keywords

Access to Document

Fingerprint

Projects

Treatment of psoriasiform-like skin inflammation with diacerein

Cite this